Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Breast Neoplasms 22 Prostatic Neoplasms 11 Osteoporosis 8 Vitamin D Deficiency 7 Polycystic Ovary Syndrome 7 Precursor Cell Lymphoblastic Leukemia-Lymphoma 5 Colonic Neoplasms 5 Obesity 3 Neoplasms 3 Neoplasm Metastasis 3 Lung Neoplasms 3 Inflammation 3 Colorectal Neoplasms 3 Carcinoma, Hepatocellular 3 Bone Diseases, Metabolic 3 Multiple Endocrine Neoplasia Type 1 2 Motor Activity 2 Lymphoma 2 Leukemia 2 Leiomyoma 2 Giant Cell Tumor of Bone 2 Gastrointestinal Neoplasms 2 Cardiovascular Diseases 2 Carcinoma, Transitional Cell 2 Brain Neoplasms 2 Bone Diseases 2 Warts 1 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1

Interventions

Cyclophosphamide 22 blinatumomab 18 Cytarabine 15 fludarabine 13 Azacitidine 12 venetoclax 10 fludarabine phosphate 10 Rituximab 8 Lenalidomide 7 Dexamethasone 7 Methotrexate 6 Daunorubicin 6 Mercaptopurine 5 daratumumab 4 Whole-Body Irradiation 4 Vincristine 4 Melphalan 4 Idarubicin 4 Etoposide 4 Busulfan 4 pembrolizumab 3 obinutuzumab 3 Radiotherapy 3 Maintenance 3 Immunotherapy, Adoptive 3 Imatinib Mesylate 3 Granulocyte Colony-Stimulating Factor 3 Drug Therapy 3 Cladribine 3 Asparaginase 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Neoplasm, Residual × Vitamin D × Clear all

NCT00172068 2009-12-23

MRD-1

Novartis

Phase 2 Terminated

Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡